 | |
| Company type | Subsidiary of Hoffmann-La Roche |
|---|---|
| Industry | Biotechnology Pharmaceutical |
| Founded | 2013 |
| Founders | Katherine A. High Jeffrey Marrazzo Jean Bennett J Fraser Wright Beverly Davidson Jennifer Wellman |
| Headquarters | Philadelphia, Pennsylvania |
| Revenue |  $64 million (2018) |
| -$78 million (2018) | |
| Total assets | $814 million (2018) |
| Total equity |  $496 million (2018) |
Number of employees | 368 (2019) |
| Parent | Hoffmann-La Roche |
| Website | sparktx |
| Footnotes / references [1] | |
Spark Therapeutics, Inc. is a developer of gene therapy treatments, which treat debilitating genetic diseases.[1] It was founded in 2013 and has been a subsidiary of Hoffmann-La Roche since 2020.